Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Ensysce Biosciences, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 16 | 18 | +2 |
| Shares | 3.16M | 3.38M | +222.0K (+7.0%) |
| Value | $9.56M | $15.9M | +$6.31M (+66.0%) |
New holders (8)
Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 301,299 | $1.42M | 0.00% |
| Goldman Sachs Group Inc | 170,648 | $802.0K | 0.00% |
| State Street Corp | 34,900 | $164.0K | 0.00% |
| UBS Group AG | 9,861 | $46.0K | 0.00% |
| JPMorgan Chase & Co | 1,314 | $6.00K | 0.00% |
| BlackRock Inc. | 561 | $3.00K | 0.00% |
| FinTrust Capital Advisors, LLC | 350 | $2.00K | 0.00% |
| Bank of America Corp | 91 | $0 | 0.00% |
Sold out (6)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Founders Fund Ill Management, LLC | 143,575 | $435.0K |
| Millennium Management LLC | 38,065 | $115.0K |
| FNY Investment Advisers, LLC | 34,113 | $103.0K |
| Virtu Financial LLC | 25,807 | $78.0K |
| Two Sigma Securities, LLC | 11,228 | $34.0K |
| Covington Capital Management | 4,800 | $15.0K |